Loss of lipid kinase pi5p4k gamma restricts tumor growth
AssigneesCornell University, The Brigham and Women's Hospital, Inc.
InventorsLewis C. Cantley, Vijay Kumar Kuchroo, Markus Alexander Schramm, Karen Olivia Dixon
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for inhibiting, degrading, knocking down or knocking out pip4k2c nucleic acids or Pip4k2c protein. Such compositions and methods are useful for treating and inhibiting the onset of cancer.
Claims35
A population of modified cells comprising knockdown or knockout of the cells' endogenous pip4k2c, wherein the modified cells comprise myeloid cells, lymphocytes, regulatory T cells, dendritic cells, bone marrow cells, granulocytes, basophils, eosinophils, neutrophils, monocytes, mast cells, erythrocytes, macrophages, platelets, tumor cells, malignant cells or a combination thereof.
A composition comprising one or more agents that can modify, degrade, or inhibit Pip4k2c protein or a pip4k2c nucleic acid.
A method comprising depleting, degrading, or inhibiting PIP4K2C in one or more cells of a subject.
Dependencies are inferred from the claim text.